XBiotech's COVID-19 therapy shows promise against virus variant, shares rise

XBiotech

21/01/2021 14:00

** Shares of drug developer  XBIT.O  rise 20.9% to $19.80
premarket
    ** XBIT says its experimental COVID-19 therapy has
capability to neutralize and treat new variant of the virus that
emerged in UK (https://refini.tv/3nZ0tBy)
    ** Co's data is from its True Human antibodies, derived
without modification from humans who possess natural immunity to
certain diseases
    ** True Human antibodies specifically targets spike protein
of virus and potently neutralizes its ability to infect cells
    ** In studies, antibody bound to the mutant spike protein
with same high affinity as it does to the original COVID-19
virus - XBIT
    ** In Nov, co reported data showing that True Human antibody
therapy demonstrated effective anti-virus activity against
COVID-19  urn:newsml:reuters.com:*:nL4N2I53BA
    ** Up to last close, stock up 4.6% so far this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))